Modality
Radioligand
MOA
TROP-2 ADC
Target
APOC3
Pathway
RNA Splicing
Heart FailureOvarian CaHNSCC
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
Oct 2017
→ Mar 2028
Phase 1Current
NCT07126250
2,607 pts·Heart Failure
2017-10→2028-03·Active
NCT04136251
519 pts·HNSCC
2024-05→TBD·Terminated
3,126 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-182.0y awayPh2 Data· Heart Failure
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Active
P1/2
Termina…
Catalysts
Ph2 Data
2028-03-18 · 2.0y away
Heart Failure
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07126250 | Phase 1/2 | Heart Failure | Active | 2607 | HbA1c |
| NCT04136251 | Phase 1/2 | HNSCC | Terminated | 519 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 |